Mangoceuticals, Inc. (NASDAQ:MGRX) Short Interest Update

Mangoceuticals, Inc. (NASDAQ:MGRX) saw a significant decrease in short interest during the month of March. As of March 31st, there was short interest totaling 1,016,081 shares, a decrease of 16.9% from the March 15th total of 1,222,450 shares. Based on an average daily trading volume, of 28,351,294 shares, the short-interest ratio is currently 0.0 days. Approximately 7.1% of the shares of the stock are short sold.

Mangoceuticals Price Performance

NASDAQ MGRX traded down $0.04 during trading hours on Friday, reaching $0.44. The company’s stock had a trading volume of 540,031 shares, compared to its average volume of 17,371,460. The firm has a market capitalization of $7.43 million, a price-to-earnings ratio of -0.17 and a beta of 2.54. Mangoceuticals has a 1-year low of $0.16 and a 1-year high of $2.88. The company’s 50-day moving average is $0.39 and its two-hundred day moving average is $1.00.

Mangoceuticals (NASDAQ:MGRX) last released its quarterly earnings results on Wednesday, April 1st. The company reported $0.13 earnings per share for the quarter. The company had revenue of $0.09 million during the quarter. Mangoceuticals had a negative return on equity of 109.38% and a negative net margin of 4,536.70%.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Mangoceuticals in a research note on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has an average rating of “Sell”.

Institutional Investors Weigh In On Mangoceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Virtu Financial LLC acquired a new stake in shares of Mangoceuticals in the fourth quarter valued at $25,000. Ikarian Capital LLC acquired a new stake in shares of Mangoceuticals in the fourth quarter valued at $102,000. Boothbay Fund Management LLC acquired a new stake in shares of Mangoceuticals in the fourth quarter valued at $28,000. Armistice Capital LLC acquired a new stake in Mangoceuticals during the 4th quarter worth approximately $1,137,000. Finally, Jane Street Group LLC purchased a new position in Mangoceuticals in the 4th quarter valued at approximately $35,000. Institutional investors and hedge funds own 56.72% of the company’s stock.

About Mangoceuticals

Mangoceuticals, Inc develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program.